Supplier qualification checklist for GMP‑grade isotopically labelled compounds in 2026

What elements must a 2026 supplier qualification checklist for GMP‑grade isotopically labelled compounds contain?

A comprehensive checklist should cover the following domains:

1. Regulatory and certification status – Verify current ISO 9001:2015, ISO 13485, and GMP certifications, as well as REACH and TSCA registrations. Documentation must be up‑to‑date and include the latest audit reports.^1
2. Quality management system (QMS) – Review the supplier’s QMS for change control, deviation handling, and corrective‑and‑preventive action (CAPA) procedures. Evidence of a documented risk‑based approach is essential.
3. Analytical capability – Confirm that the supplier can generate full analytical packages for isotopically labelled material, including ^13C/^15N/^2H NMR, HPLC purity, and GC‑MS impurity profiling. Access to validated methods and instrument calibration records should be provided.
4. Documentation and traceability – Require a Certificate of Analysis (CoA) for each batch, a Safety Data Sheet (SDS) compliant with GHS, and a batch‑level traceability matrix linking raw materials to the final product.
5. Supply chain security – Assess the origin of the isotopic precursor, storage conditions (e.g., temperature‑controlled logistics), and any subcontractors involved in the synthesis.
6. Environmental, health and safety (EHS) compliance – Ensure the supplier follows local and EU waste‑disposal regulations and provides evidence of employee training on hazardous isotopes.
7. Financial and operational stability – Review recent financial statements and production capacity to gauge the ability to meet long‑term demand.

These items reflect the consensus of 2026 industry guidance on supplier qualification.^2^4

How should audit frequency and scope be defined for isotopic compound suppliers?

Audit frequency is typically risk‑based. High‑risk suppliers—those providing > 5 kg of labelled material per year or custom‑synthesised compounds—should undergo a full on‑site GMP audit at least once every 24 months. Lower‑risk vendors may be audited biennially via a remote document review, supplemented by a targeted on‑site visit every 48 months. The audit scope must include:

• Review of the QMS against ISO 9001:2015 and GMP clauses.
• Verification of analytical method validation records (e.g., NMR, HPLC).
• Inspection of storage facilities for temperature and humidity control.
• Evaluation of waste handling for radioactive or heavy‑isotope waste.
• Assessment of supplier’s internal audit programme and corrective‑action records.

The 2026 checklist recommends a minimum of 30 audit points for full‑scale inspections, with a reduced set of 15 points for remote reviews.^1

What documentation should be retained for each batch of GMP‑grade isotopically labelled compound?

For every batch, the following documents must be retained for a minimum of five years, in line with GMP record‑keeping requirements:

| Document | Minimum retention period | |----------|--------------------------| | Batch Manufacturing Record (BMR) | 5 years | | Certificate of Analysis (CoA) | 5 years | | Safety Data Sheet (SDS) | 5 years | | Analytical method validation reports (NMR, HPLC, GC‑MS) | 5 years | | Supplier audit report (most recent) | 5 years | | Shipping and receipt logs (including temperature data) | 5 years |

Electronic storage in a validated LIMS is acceptable, provided audit trails are immutable.

How does the 2026 regulatory landscape influence supplier qualification for isotopic compounds?

The 2026 regulatory updates place greater emphasis on traceability and data integrity. The European Medicines Agency (EMA) now requires explicit labelling of isotopic enrichment levels on the CoA, and the US FDA has tightened requirements for TSCA reporting of heavy‑isotope waste. Additionally, the updated GHS classification mandates that isotopic compounds be flagged with a specific hazard statement (e.g., H315 – “Causes skin irritation”). Suppliers must therefore demonstrate compliance with these newer provisions during qualification.^2

What are the key performance indicators (KPIs) to monitor after supplier qualification?

Post‑qualification, organisations should track the following KPIs to ensure ongoing compliance:

• On‑time delivery rate – Target ≥ 95 %.
• Batch failure rate – Measured as the proportion of batches failing CoA specifications; aim < 2 %.
• Audit finding closure time – Average time to resolve non‑conformances; target ≤ 30 days.
• Change‑control lead time – Time from change request to implementation; target ≤ 45 days.
• EHS incident frequency – Number of safety incidents per 1 000 kg of material handled; aim for zero.

Regular KPI review (quarterly) enables early detection of supplier performance drift and supports continuous improvement.

Frequently asked questions

Q1: How often should CoA data be re‑validated for isotopic enrichment? A: Re‑validation is recommended whenever the enrichment level changes by more than 5 % or after any major equipment qualification.

Q2: Can a remote audit replace an on‑site visit for low‑risk suppliers? A: Yes, provided the remote audit includes full document review, video walkthrough of critical areas, and a third‑party verification of analytical data.

Q3: What is the minimum acceptable purity for a GMP‑grade ^13C‑labelled compound? A: Purity requirements are product‑specific, but most GMP applications require ≥ 98 % chemical purity and ≤ 0.1 % isotopic impurity.

Q4: Does Molekula perform its own GMP audits on suppliers? A: Molekula follows the same risk‑based audit schedule outlined above and retains all audit records in its LIMS for regulatory inspection.